Identa Corp
IDenta Corp. operates as a detection and forensic science company. The company offers drug testing kits, explosives testing kits, aero chamber sniffer, forensic, urine drug testing, and saliva drug testing products. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. The company … Read more
Identa Corp (IDTA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.247x
Based on the latest financial reports, Identa Corp (IDTA) has a cash flow conversion efficiency ratio of -0.247x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-184.21K) by net assets ($747.08K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Identa Corp - Cash Flow Conversion Efficiency Trend (2002–2023)
This chart illustrates how Identa Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Identa Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Identa Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XSLR
F:XSLR
|
N/A |
|
EVIO Inc
PINK:EVIO
|
-0.036x |
|
VOGO S.A. EO-125
F:7CY
|
N/A |
|
CWTH BK AUSTRALIA
MU:CWW
|
N/A |
|
Wirecard AG
PINK:WRCDF
|
0.091x |
|
RangDong Plastic JSC
VN:RDP
|
N/A |
|
Biovaxys Technology Corp
OTCQB:BVAXF
|
0.003x |
|
One World Pharma Inc
OTCQB:OWPC
|
0.028x |
Annual Cash Flow Conversion Efficiency for Identa Corp (2002–2023)
The table below shows the annual cash flow conversion efficiency of Identa Corp from 2002 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $516.12K | $-137.63K | -0.267x | -229.96% |
| 2022-12-31 | $459.63K | $94.31K | 0.205x | +199.20% |
| 2021-12-31 | $430.01K | $-88.95K | -0.207x | -116.31% |
| 2020-12-31 | $340.37K | $431.79K | 1.269x | +45.56% |
| 2019-12-31 | $-16.86K | $-14.69K | 0.872x | +109.80% |
| 2018-12-31 | $-16.73K | $148.81K | -8.897x | -2021.85% |
| 2017-12-31 | $-162.56K | $-75.25K | 0.463x | -99.68% |
| 2016-12-31 | $-1.68K | $-240.54K | 142.925x | +39917.13% |
| 2015-12-31 | $-391.30K | $-139.75K | 0.357x | -95.64% |
| 2014-12-31 | $-93.54K | $-765.68K | 8.186x | +6231.42% |
| 2011-12-31 | $-1.33 Million | $-171.85K | 0.129x | -18.65% |
| 2010-12-31 | $-1.15 Million | $-182.04K | 0.159x | +25.00% |
| 2003-12-31 | $-1.43 Million | $-182.04K | 0.127x | +6.05% |
| 2002-12-31 | $-1.52 Million | $-182.04K | 0.120x | -- |